Stanford Univerity

Stanford, California 94305

We've found

1 trials

at this facility

Darunavir/Cobicistat and Dolutegravir to Maintain Virologic Suppression and Reduce NRTI-associated Toxicity

Status: Upcoming, Phase II, III
Updated: 7/14/2015

from

Stanford, CA

Use our guide to learn which trials are right for you!